Stephens Initiates Twist Bioscience (TWST) With Overweight Rating, Sets $41 PT

Twist Bioscience Corporation (NASDAQ:TWST) is one of the best gene-editing stocks to buy according to hedge funds. On November 4, Steven Etoch, an analyst at Stephens, began coverage of Twist Bioscience Corporation (NASDAQ:TWST). Etoch assigned an Overweight rating on the stock and a $41 price target. The analyst cited Twist’s “differentiated, technology-driven DNA synthesis platform” as a key factor in the decision. The platform serves several markets, including drug discovery, next-generation sequencing (NGS), and synthetic biology. This platform is powered by silicon chip technology, which Etoch pointed out gives Twist advantages in cost, speed, and the scale of DNA production.

According to the analyst, Twist’s innovation spurred strong revenue growth – 22.7% over the past year and a five-year CAGR of 42%. Etoch noted further that while the gene editing landscape is competitive, Twist’s cost leadership and investments are helping it gain market share. The analyst expects the company to reach adjusted EBITDA break-even by the end of fiscal year 2026.

Etoch identified NGS as a major growth opportunity, particularly as its adoption expands in areas such as liquid biopsy and minimal residual disease (MRD) monitoring. He also cited expansion into adjacent markets as a way that Twist is strengthening its customer relationships.

Twist Bioscience Corporation (NASDAQ:TWST) is a synthetic biology company. It manufactures DNA at scale using a proprietary silicon-based platform. This enables rapid gene synthesis for applications in drug discovery, diagnostics, and precision medicine. Its main products are custom DNA sequences and gene libraries.

READ NEXT: 10 Best European Bank Stocks to Buy Now and 11 Best Solar Energy Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.